The new information will be provided to the European Society of Medical Oncology
4D pharma PLC (AIM: DDDD, NASDAQ: LBPS) has announced that it will display two poster presentations at an upcoming cancer conference providing biomarker data on its core asset, MRx0518.
The first indicates the drug’s potential to overcome a form of acquired resistance to cancer treatment.
The second reveals the “potent activity” of orally administered MRx0518 directly on the human immune system.
The two posters will be presented at the congress of the European Society of Medical Oncology (ESMO), from Thursday 16 September. They will be on the company’s website from that date.
MRx0518 is a new class of drugs called a living biotherapeutic product (LBP), derived from the microbiome, which is an ecosystem of bacteria found primarily in the human gut.
Supplied in a capsule taken orally, it stimulates the body’s immune system, directing it to produce cytokines and cells that are known to attack tumors.
It is currently being evaluated in three clinical trials in cancer patients.
âAt the heart of 4D pharma’s platform is the importance of understanding the impact of living biotherapies on human biology to rationally select and develop candidates, predict and measure the response,â said the scientific director of the company, Dr. Alex Stevenson.
âThese new biomarker data provide us with essential insights into the biological and mechanistic impact of MRx0518 therapy in patients with various solid tumors.
“These new findings indicate the potential to predict which patients are most likely to respond to MRx0518 therapy based on tumor biology.”
For more information on the posters click here